Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01326702 · OUTCOME

Overall Survival (Phase IIa)

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · Source last updated 2019-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 30 days post-treatment

What was measured

Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed.

Analysis population: Data were not collected

Groups in this outcome

Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg

Bendamustine 70 mg/m2, ABT-888 50 mg

Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg

Bendamustine 90 mg/m2, ABT-888 50 mg

Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID

Bendamustine 90 mg/m2, ABT-888 100 mg BID

Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID

Bendamustine 90 mg/m2, ABT-888 150 mg BID

Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID

Bendamustine 90 mg/m2, ABT-888 200 mg BID

Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID

Bendamustine 90 mg/m2, ABT-888 300 mg BID

Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID

Bendamustine 90 mg/m2, ABT-888 400 mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg0
Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg0
Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID0
Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID0
Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID0
Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID0
Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      0
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      0
    7. group Id
      OG006
      value
      0
    units
    Participants
description
Kaplan-Meier estimates will be calculated and log-rank tests will be employed when certain comparisons are needed.
groups
  1. description
    Bendamustine 70 mg/m2, ABT-888 50 mg
    id
    OG000
    title
    Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg
  2. description
    Bendamustine 90 mg/m2, ABT-888 50 mg
    id
    OG001
    title
    Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg
  3. description
    Bendamustine 90 mg/m2, ABT-888 100 mg BID
    id
    OG002
    title
    Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID
  4. description
    Bendamustine 90 mg/m2, ABT-888 150 mg BID
    id
    OG003
    title
    Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID
  5. description
    Bendamustine 90 mg/m2, ABT-888 200 mg BID
    id
    OG004
    title
    Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID
  6. description
    Bendamustine 90 mg/m2, ABT-888 300 mg BID
    id
    OG005
    title
    Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID
  7. description
    Bendamustine 90 mg/m2, ABT-888 400 mg BID
    id
    OG006
    title
    Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID
population Description
Data were not collected
reporting Status
POSTED
time Frame
Up to 30 days post-treatment
title
Overall Survival (Phase IIa)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice